Close Menu
Daily Guardian
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
What's On

Ozi Amanat, Backer of Neuralink, SpaceX, xAI, Shield AI, Lambda, and Tenstorrent, Expands K2 Global’s Frontier Technology Investments

September 18, 2026

MP calls on New Brunswick to reject proposed AI data centre in open letter to premier

September 18, 2026

Appeal hearing continues over fired Regina police chief

September 18, 2026

Manitobans brace for dark mornings, lighter evenings after time change nixed

September 18, 2026

2 sudden deaths prompt public safety warning from Halifax police

September 18, 2026
Facebook X (Twitter) Instagram
Finance Pro
Facebook X (Twitter) Instagram
Daily Guardian
Subscribe
  • Home
  • News
  • Politics
  • Business
  • Entertainment
  • Lifestyle
  • Health
  • Sports
  • Technology
  • Climate
  • Auto
  • Travel
  • Web Stories
Daily Guardian
Home » SuspendIt® Is Now a USP Verified Excipient
Press Release

SuspendIt® Is Now a USP Verified Excipient

By News RoomDecember 10, 20252 Mins Read
SuspendIt® Is Now a USP Verified Excipient
Share
Facebook Twitter LinkedIn Pinterest Email

Houston, TX, Dec. 10, 2025 (GLOBE NEWSWIRE) — PCCA, a leading supplier of pharmaceutical ingredients, announced today the U.S. Pharmacopeia (USP) has verified SuspendIt® — adding to its growing family of proprietary compounding bases that have earned this independent mark of quality assurance. Earlier this year, PCCA became the first FDA-registered supplier to complete the USP Ingredient Verification Program for Excipients for compounding bases, receiving verification for its LoxOral® and Anhydrous SuspendIt® bases.

“This verification demonstrates our continued commitment to our ‘Quality without Compromise’ core value,” said PCCA CEO Gus Bassani, PharmD. “Confirmation of quality through independent verification reinforces our promise to pharmacies and patients to deliver purity and consistency with our products. Our goal is to help our members compound with confidence.”

PCCA’s third USP Verified Excipient, SuspendIt®, is an all-in-one, aqueous compounding base that is specifically designed for oral suspension formulations. With its innovative technology, SuspendIt® enables rapid redispersion of APIs with gentle agitation, reduces sedimentation and helps support consistent dosing. Free of gluten, alcohol, parabens and dyes, SuspendIt® is suitable for a wide range of patients with sensitivity concerns.

“We are investing our time and efforts into completing the USP Verification process to verify the quality of our bases, even though regulations do not require it,” Bassani said. “We plan to continue pursuing this verification for additional PCCA proprietary bases.”

PCCA invests heavily in research and development to create unique, patented bases to enhance therapeutic outcomes, while providing independent compounding pharmacies and health systems with quality products, expert guidance and innovative approaches to delivering personalized medicine.

ABOUT PCCA
PCCA supports the creation of personalized medicine and innovative products that make a difference in patients’ lives. As a complete resource for independent compounding pharmacies and health systems, PCCA provides high-quality products, education and support to more than 3,000 pharmacy members throughout the United States, Canada, Australia and other countries around the world. Incorporated in 1981 by a network of pharmacists, PCCA has supported pharmacy compounding for more than 40 years. Learn more at pccarx.com.

  • SuspendIt® Is Now a USP Verified Excipient

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

Ozi Amanat, Backer of Neuralink, SpaceX, xAI, Shield AI, Lambda, and Tenstorrent, Expands K2 Global’s Frontier Technology Investments

CT UAV Successfully Designs 230 kg Heavy-Lift Transport UAV, Capable of Carrying 100 kg

First Atlantic Nickel & Cobalt Raises 6.15 Million Dollars in No-Warrant, Non-Brokered Private Placement to Accelerate Mining Exploration and Development at Pipestone XL Nickel-Cobalt Alloy (Awaruite) Project in Newfoundland

Coming Home Project and Birds Eye View Project Complete Groundbreaking Ayahuasca Retreat for Veterans

Elite Asia Group Unveils New Integrative Wellness Approach Combining Traditional Chinese Medicine and AI Technology

Remittix Moves Closer to Launch Milestone as XRP Stabilizes Near $1.33 After CLARITY Act Setback

ARDX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ardelyx (NASDAQ: ARDX) Investors of Securities Class Action Lawsuit Deadline on November 16, 2026

Native Springs Expands Smart Home Technology Coverage with New 2026 Consumer Resource

Shenzhen Jewellok Technology Unveils Integrated Laboratory Gas Pipeline and Gas Scrubber Systems

Editors Picks

MP calls on New Brunswick to reject proposed AI data centre in open letter to premier

September 18, 2026

Appeal hearing continues over fired Regina police chief

September 18, 2026

Manitobans brace for dark mornings, lighter evenings after time change nixed

September 18, 2026

2 sudden deaths prompt public safety warning from Halifax police

September 18, 2026

Latest News

CT UAV Successfully Designs 230 kg Heavy-Lift Transport UAV, Capable of Carrying 100 kg

September 18, 2026

OpenAI and Microsoft knew they were starting a ‘doom loop’ for the web

September 18, 2026

First Atlantic Nickel & Cobalt Raises 6.15 Million Dollars in No-Warrant, Non-Brokered Private Placement to Accelerate Mining Exploration and Development at Pipestone XL Nickel-Cobalt Alloy (Awaruite) Project in Newfoundland

September 18, 2026
Facebook X (Twitter) Pinterest TikTok Instagram
© 2026 Daily Guardian Canada. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.

Go to mobile version